Inhibition of the Bacterial Enoyl Reductase FabI by Triclosan: A Structure-Reactivity Analysis of FabI Inhibition by Triclosan Analogues

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 509-518

  Sivaraman, Sharada ^a   Sullivan, Todd J ^a   Johnson, Francis ^a   Novichenok, Polina ^a   Cui, Guanglei ^a   Simmerling, Carlos ^a   Tonge, Peter J ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENOXYPHENOL; 5 CHLORO 2 PHENOXYPHENOL; 5 FLUORO 2 PHENOXYPHENOL; 5 METHYL 2 PHENOXYPHENOL; BACTERIAL ENZYME; CHLORINE; ENOYL REDUCTASE; FABI PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXIDOREDUCTASE; PHENOL DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TRICLOSAN; TRICLOSAN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG BINDING; ENZYME BINDING; ENZYME INHIBITION; ESCHERICHIA COLI; FATTY ACID SYNTHESIS; INHIBITION KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PKA; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACTERIA; CRYSTALLOGRAPHY, X-RAY; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTATION; NAD; OXIDOREDUCTASES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TRICLOSAN;

EID: 1642540581     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030182i     Document Type: Article

References (37)

1. Heath, R. J.; White, S. W.; Rock, C. O. Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. 2001, 40, 467-497.
2. Rock, C. O.; Cronan, J. E. Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. Biochim. Biophys. Acta 1996, 1302, 1-16.
3. Campbell, J. W.; Cronan, J. E., Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 2001, 55, 305-332.
4. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; Payne, D. J. et al. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydro-pyrido[3,4-b]indoles as potential antibacterial agents. Bioorg. Med. Chem. Lett. 2001, 11, 2241-2244.
5. Heerding, D. A.; Chan, G.; DeWolf, W. E.; Fosberry, A. P.; Janson, C. A. et al. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg. Med. Chem. Lett. 2001, 11, 2061-2065.
6. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J. et al. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 2002, 45, 3246-3356.
7. Payne, D. J.; Miller, W. H.; Berry, V.; Brosky, J.; Burgess, W. J. et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 2002, 46, 3118-3124.
8. Schweizer, H. P. Triclosan: a widely used biocide and its link to antibiotics. FEMS Microbiol. Lett. 2001, 202, 1-7.
9. Regos, J.; Zak, O.; Solf, R.; Vischer, W. A.; Weirich, E. G. Antimicrobial spectrum of triclosan, a broad-spectrum antimicrobial agent for topical application. II. Comparison with some other antimicrobial agents. Dermatologica 1979, 158, 72-79.
10. Vischer, W. A.; Regos, J. Antimicrobial spectrum of Triclosan, a broad-spectrum antimicrobial agent for topical application. Zentralbl. Bakteriol. [Orig A] 1974, 226, 376-389.
11. McMurry, L. M.; Oethinger, M.; Levy, S. B. Triclosan targets lipid synthesis. Nature 1998, 394, 531-532.
12. Heath, R. J.; Yu, Y. T.; Shapiro, M. A.; Olson, E.; Rock, C. O. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 1998, 273, 30316-30320.
13. Ward, W. H.; Holdgate, G. A.; Rowsell, S.; McLean, E. G.; Pauptit, R. A. ; Clayton, E.; Nichols, W. W.; Colls, J. G.; Minshull, C. A.; Jude, D. A.; Mistry, A.; Timms, D.; Camble, R.; Hales, N. J.; Britton, C. J.; Taylor, I. W. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 1999, 38, 12514-12525.
14. Levy, C. W.; Roujeinikova, A.; Sedelnikova, S.; Baker, P. J.; Stuitje, A. R. et al. Molecular basis of triclosan activity. Nature 1999, 398, 383-384.
15. Stewart, M. J.; Parikh, S.; Xiao, G.; Tonge, P. J.; Kisker, C. Structural basis and mechanism of enoyl reductase inhibition by triclosan. J. Mol. Biol. 1999, 290, 859-865.
16. Roujeinikova, A.; Levy, C. W.; Rowsell, S.; Sedelnikova, S.; Baker, P. J.; Minshull, C. A.; Mistry, A.; Colls, J. G.; Camble, R.; Stuitje, A. R.; Slabas, A. R.; Rafferty, J. B.; Pauptit, R. A.; Viner, R.; Rice, D. W. Crystallographic analysis of triclosan bound to enoyl reductase. J. Mol. Biol. 1999, 294, 527-535.
17. Heath, R. J.; Rock, C. O. A triclosan-resistant bacterial enzyme. Nature 2000, 406, 145-146.
18. Heath, R. J.; Su, N.; Murphy, C. K.; Rock, C. O. The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis. J. Biol. Chem. 2000, 275, 40128-40133.
19. Heath, R. J.; Li, J.; Roland, G. E.; Rock, C. O. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J. Biol. Chem. 2000, 275, 4654-4659.
20. Marcinkeviciene, J.; Jiang, W.; Kopcho, L. M.; Locke, G.; Luo, Y. et al. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene. Arch. Biochem. Biophys. 2001, 390, 101-108.
21. McMurry, L. M.; McDermott, P. F.; Levy, S. B. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob. Agents Chemother. 1999, 43, 711-713.
22. Parikh, S. L.; Xiao, G.; Tonge, P. J. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 2000, 39, 7645-7650.
23. Kuo, M. R.; Morbidoni, H. R.; Alland, D.; Sneddon, S. F.; Gourlie, B. B. et al. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J. Biol. Chem. 2003, 278, 20851-20859.
24. Surolia, N.; Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 2001, 7, 167-173.
25. Kapoor, M.; Dar, M. J.; Surolia, N.; Surolia, A. Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors. Biochem. Biophys. Res. Commun. 2001, 289, 832-837.
26. Perozzo, R.; Kuo, M.; bir Singh Sidhu, A.; Valiyaveettil, J. T.; Bittman, R.; Jacobs, W. R., Jr.; Fidock, D. A.; Sacchettini, J. C. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl ACP reductase. J. Biol. Chem. 2002, 277, 13106.
27. Liu, B.; Wang, Y.; Fillgrove, K. L.; Anderson, V. E. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother. Pharmacol. 2002, 49, 187-193.
28. Heath, R. J.; Rubin, J. R.; Holland, D. R.; Zhang, E.; Snow, M. E. et al. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 1999, 274, 11110-11114.
29. Qiu, X.; Janson, C. A.; Court, R. I.; Smyth, M. G.; Payne, D. J. et al. Molecular basis for triclosan activity involves a flipping loop in the active site. Protein Sci. 1999, 8, 2529-2532.
30. Sivaraman, S.; Zwahlen, J.; Bell, A. F.; Hedstrom, L.; Tonge, P. J. Structure-Activity Studies of the Inhibition of FabI, the Enoyl Reductase from Escherichia coli, by Triclosan: Kinetic Analysis of Mutant FabIs. Biochemistry 2003, 42, 4406-4413.
31. Morrison, J. F.; Walsh, C. T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. 1988, 61, 201-301.
32. Baldock, C.; Rafferty, J. B.; Sedelnikova, S. E.; Baker, P. J.; Stuitje, A. R.; Slabas, A. R. A mechanism of drug action revealed by structural studies of enoyl reductase. Science 1996, 274, 2107-2110.
33. Levy, C. W.; Baldock, C.; Wallace, A. J.; Sedelnikova, S.; Viner, R. C.; Clough, J. M.; Stuitje, A. R.; Slabas, A. R.; Rice, D. W.; Rafferty, J. B. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase. J. Mol. Biol. 2001, 309, 171-180.
34. Roujeinikova, A.; Sedelnikova, S.; de Boer, G. J.; Stuitje, A. R.; Slabas, A. R.; Rafferty, J. B.; Rice, D. W. Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition. J. Biol. Chem. 1999, 274, 30811-30817.
35. Marcoux, J.-F.; Doye, S.; Buchwald, S. L. J. Am. Chem. Soc. 1997, 119, 10539-10540.
36. Neumeyer, J. L.; Baindur, N.; Yuan, J.; Booth, G.; Seeman, P. et al. Development of a high affinity and stereoselective photo-affinity label for the D-1 dopamine receptor: synthesis and resolution of 7-[125I]iodo-8-hydroxy-3-methyl-1-(4′-azidophenyl)-2,3,4, 5-tetrahydro-1H-3-benzazepine. J. Med. Chem. 1990, 33, 521-526.
37. Parikh, S.; Moynihan, D. P.; Xiao, G.; Tonge, P. J. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry 1999, 38, 13623-13634.